Global Search | Novartis

Hide Filters

Showing 2671 results

Press Release / Oct 25, 2016

Novartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentiels

Chiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa…
Press Release / Oct 25, 2016

Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster

Dank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +…
Press Release / Oct 25, 2016

Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301…
Press Release / Oct 31, 2016

Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product

Basel, October 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "…
Press Release / Nov 01, 2016

Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared…
Press Release / Nov 14, 2016

Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain

Cosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]* New data show that with Cosentyx the high…
Press Release / Nov 14, 2016

Novartis improves ranking in 2016 Access to Medicine Index

Novartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income…
Press Release / Nov 15, 2016

New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths

Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril[1]…
Press Release / Nov 14, 2016

Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

Priority Review based on data from the largest clinical trials conducted to date in each indication[1],[2] Designation will shorten FDA expected review time to within six months[3]; EMA also…
Press Release / Nov 16, 2016

Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer

First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia Sub-group analyses from pivotal MONALEESA-2 trial of…